High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

Don M. Benson, Patrick J. Elder, Thomas S. Lin, William Blum, Sam Penza, Belinda Avalos, Edward Copelan, Sherif Farag

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age = 56.1) underwent HDC with ASCT using either BCV (n = 62) or HDM (n = 48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.

Original languageEnglish (US)
Pages (from-to)1077-1083
Number of pages7
JournalLeukemia Research
Volume31
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Busulfan
Melphalan
Stem Cell Transplantation
Etoposide
Multiple Myeloma
Cyclophosphamide
Stem Cells
Transplants
Drug Therapy
Disease-Free Survival
Survival Rate
Survival

Keywords

  • Autologous transplantation
  • Conditioning regimens
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. / Benson, Don M.; Elder, Patrick J.; Lin, Thomas S.; Blum, William; Penza, Sam; Avalos, Belinda; Copelan, Edward; Farag, Sherif.

In: Leukemia Research, Vol. 31, No. 8, 08.2007, p. 1077-1083.

Research output: Contribution to journalArticle

Benson, Don M. ; Elder, Patrick J. ; Lin, Thomas S. ; Blum, William ; Penza, Sam ; Avalos, Belinda ; Copelan, Edward ; Farag, Sherif. / High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. In: Leukemia Research. 2007 ; Vol. 31, No. 8. pp. 1077-1083.
@article{54e598f1ba7a43c899f5f3e3c77dae1c,
title = "High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma",
abstract = "High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age = 56.1) underwent HDC with ASCT using either BCV (n = 62) or HDM (n = 48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.",
keywords = "Autologous transplantation, Conditioning regimens, Multiple myeloma",
author = "Benson, {Don M.} and Elder, {Patrick J.} and Lin, {Thomas S.} and William Blum and Sam Penza and Belinda Avalos and Edward Copelan and Sherif Farag",
year = "2007",
month = "8",
doi = "10.1016/j.leukres.2006.08.018",
language = "English (US)",
volume = "31",
pages = "1077--1083",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

AU - Benson, Don M.

AU - Elder, Patrick J.

AU - Lin, Thomas S.

AU - Blum, William

AU - Penza, Sam

AU - Avalos, Belinda

AU - Copelan, Edward

AU - Farag, Sherif

PY - 2007/8

Y1 - 2007/8

N2 - High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age = 56.1) underwent HDC with ASCT using either BCV (n = 62) or HDM (n = 48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.

AB - High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age = 56.1) underwent HDC with ASCT using either BCV (n = 62) or HDM (n = 48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.

KW - Autologous transplantation

KW - Conditioning regimens

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=34249943589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249943589&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.08.018

DO - 10.1016/j.leukres.2006.08.018

M3 - Article

C2 - 17070906

AN - SCOPUS:34249943589

VL - 31

SP - 1077

EP - 1083

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -